The backbone of clonal evolution model claims that every individual malignant cell has the potential to initiate a new neoplasm. Yet, the cancer stem cell theory confirms that only a few number of stem-like cancer cells can initiate a new neoplasm with all clones of the original neoplasm. CD133 is the most commonly used marker to identify the CSCs from different malignancies. Among the important mediators of the inflammatory pathways is COX-2, which has been found to be elevated in several human cancers. The strong association of different types of cancer with some chronic inflammatory diseases confirms the influential role of inflammation in carcinogenesis.
INTRODUCTION
The way by which cancer occurs still a mysterious issue regardless all the improvements in cancer research. Nowadays the cancer stem cell (CSC) postulate is strengthened, challenging the theory of 'clonal evolution' for malignant occurrence and implying the emergence of a possible treatment for malignant neoplasms [1] .
The backbone of clonal evolution model claims that every individual malignant cell has the potential to initiate a new neoplasm [2] . Yet, the cancer stem cell theory confirms that only a few number of stem-like cancer cells can initiate a new neoplasm with all clones of the original neoplasm, while the rest of the malignant cells have restricted power of proliferation [3] . The novel recognition of precancerous stem cells (pCSCs) emphasizes that the "clonal evolution" is not paradoxical to the CSC hypothesis, but considered as an aspect of the procedure of CSC up growth [4] .
The malignant stem cell exploration is still in its beginning, many questions concerning the role of pCSC cannot be answered nowadays. Development of cancer comprises a reversible pre-cancerous phase. However the mechanism of all cancer events still under research [5] .
Different researchers have specified biomarkers on the surface of CSCs to set them a part from the rest of the tumor cells. CD133 is the most commonly used marker to identify CSCs from different malignancies [6] . CD133 is a 120 KDa, pentaspan transmembrane glycoprotein which was observed in hematopoietic stem cells. Recently the increase of CD133 expression was detected in oral cancer stem-like cells and its gradual overexpression from normal mucosa to dysplasia then carcinoma was reported [7] .
Among the other stem cell markers Oct-, and CD117 [8] . CD133 was found to be an important indicator of the future of colorectal, lung and brain tumors [9] [10] [11] . Amusingly, CD133 expression decreases during cell differentiation and the laryngeal carcinoma cell line with high CD133 expression display a stem cell features such as selfrenewal [12, 13] . The tongue squamous cell carcinoma with positive CD133 expression exhibits resistance to chemotherapy [14, 15] .
There is a strong relation between inflammation and malignant tumors. Production of inflammatory mediators creates a suitable environment for cancer appearance [16, 17] .
The strong association of different types of cancer with some chronic inflammatory diseases confirms the influential role of inflammation in carcinogenesis. Colon cancer risk is strongly related to inflammatory bowel diseases, like ulcerative colitis disease. Moreover, some anti-inflammatory drugs not only reduces the cancer occurrence but also decreases recurrence and metastasis [18] .
Among the important mediators of the inflammatory pathways is COX-2, which has been found to be elevated in several human cancers. The other inflammatory mediators involved in cancer occurrence, prostaglandins, thromboxanes and leukotrienes. Expression of prostaglandins is controlled by the activity of Cyclooxygenase family (COX) [19, 20, 21] . COX-2 is stimulated by different stimuli, such as lipopolysaccharide (LPS), interleukin-1 (IL-1), tumor necrosis factor (TNF) and epidermal growth factor (EGF)) [22, 23] . The production of COX-2 is linked to many events involved in cancer such as apoptosis resistance, uncontrolled cell growth, invasion and new blood vessels formation. prostaglandins produced by COX-2 act as immunosuppressors by decreasing the macrophage and natural killer cell mediated cytotoxicity [21, 24] .
Inflammation and cancer stem cells (CSCs) have been reported to have a strong role in breast cancer [25] . But to our knowledge this correlation has not been sufficiently studied in oral cancer development, so in this study, we aimed to find the possible correlation between the stemness (CD133+) and the inflammatory modulator (COX-2) in different grades of oral epithelial dysplasias which might help in predicting the oral cancer development.
MATERIALS AND METHODS
The cases used in this study consisted of 5 histologically normal samples of normal oral mucosa and 30 samples of oral dysplasia: 10 samples with mild epithelial dysplasia, 10 samples with moderate epithelial dysplasia and 10 samples with severe epithelial dysplasia. All cases were obtained from the archive of Oral Pathology Department, Faculty of Dentistry, Ain Shams University. Briefly, immunohistochemical staining was performed as follows: sections were deparaffinized using xylene and rehydrated in graded alcohol. Sections were applied in citrate buffer before the staining procedures. The universal kit (Lab Vision, USA) was used. Peroxidase-antiperoxidase procedure using the biotin-streptavidin system was done, 3% hydrogen peroxide was added to the section to stop the endogenous peroxidase action. The sections were immunolabelled using the primary antibodies CD133 and COX-2 (Lab Vision, Fermont CA, USA) and then incubated overnight at room temperature. Sections were washed with phosphate buffer saline (PBS) then covered by the link antibody.Then the streptavidin labeling antibody was added. After rinsing with PBS, diaminobenzidine chromogen was added to the sections and then the counterstain was added. Sections were dehydrated in a graded alcohol, then in xylene and finally mounted. All the steps for immunohistochemical quantitative evaluation were done on photomicrographs captured at a magnification of X40 using image analysis software (Image J, 1.41a, NIH, USA).
Data were checked for normality by checking the distribution of data and using tests of normality (Kolmogorov-Smirnov and Shapiro-Wilk tests). Results showed normal (parametric) distribution. Results were presented as mean, standard deviation (SD) and 95% Confidence Interval (95% CI) values. One-way ANOVA test was done to compare inbetween the different grades of oral dysplasias for each marker. Bonferroni's post-hoc test was used for pair-wise comparisons. Pearson's correlation coefficient was used to determine the correlation between CD133 and COX-2. The significance level was set at P ≤ 0.05. Statistical analysis was performed with using the Statistical Package for Social Science (SPSS 15.0) Software.
RESULTS

Immunohistochemical Results
CD133:
All the 30 cases (100%) of various grades of oral dysplasia examined in this study showed CD133 immunopositivity, while the immunohistochemical analysis of normal oral mucosa did not show any immunoreactivity ( fig.1A) .
In mild dysplasia, the expression was mainly localized to the cytoplasm of the basal cells while the suprabasal layers showed nuclear reaction in some cells ( fig.1B) . In moderate dysplasia, more expression was observed and extended to the middle one third of the surface epithelium, the reaction was mainly cytoplasmic and membranous but some cells showed a nuclear reaction ( fig.1C ). Concerning severe dysplasia, the expression was observed in the whole layers of epithelium, mainly with cytoplasmic expression and few cells showed a nuclear reaction ( fig.1D ). CD133 immunopositivity was also noted in some stromal cells in nearly all cases of oral dysplasia.
COX-2:
All the 30 cases (100%) of different grades of oral dysplasias, tested in this study revealed COX-2 immunopositivity. Immunohistochemical results of normal oral mucosa did not reveal COX-2 immunopositivity ( fig.1E ).
In mild dysplasia, the immunopositive cells are scattered among the basal and suprabasal cells exhibiting mainly cytoplasmic reaction with few cells showing nuclear reaction. A few scattered immunopositive cells were revealed among the superficial layers of the epithelium ( fig.1F ). In moderate dysplasia, cytoplasmic COX-2 immunoexpresion was extended to cover the lower third of epithelium with many scattered immunopositive cells among the other layers of the epithelium. The perinuclear reaction were intense ( fig.1G ). In severe dysplasia, nearly all the layers of the epithelium showed immunopositivity for COX-2 protein. The localization was cytoplasmic as well as perinuclear (figs.1H). COX-2 immunopositivity was also noted in some stromal cells in nearly all cases of oral dysplasia.
2-Statistical results:
For both CD133 and COX-2, there were a statistically significant difference between the different grades of oral dysplasias (P-value <0.001, Effect size = 0.956 for CD133 and 0.942 for COX-2) (table 1 and fig. 2 ). Bonferroni's post-hoc test for Pair-wise comparisons between different grades of oral dysplasias for both CD133 and COX-2 revealed that severe dysplasia group showed the statistically significantly highest mean percent. Moderate dysplasia group showed statistically significantly lower mean percent. Mild dysplasia group showed the statistically significantly lowest mean percent (table 1, fig.2 ).
Correlation between COX-2 and CD133
There was a statistically significant direct (positive) correlation between COX-2 and CD133 (r = 0.956, P-value <0.001). An increase in COX-2 percent is associated with an increase in CD133 percent and vice versa ( fig. 3 ). 
DISCUSSION
Oral squamous cell carcinoma (OSCC) is the mostly occurring neoplasm in the head and neck area accompanied with high death rates [26] .
The relation between inflammation and cancer stem cells (CSCs) has a known strong effect in breast cancer [25] . In the present research, we have examined the expression pattern of CD133 and one of the inflammatory modulators; COX-2 in oral epithelial dysplasias of different grades. We also explored the relation between the presence of both molecular markers.
In this study, CD133 was highly expressed in the different grades of oral epithelial dysplasias in comparison to the normal oral epithelium, which revealed a negative staining of CD133. A gradual increase in the expression was detected where the mild dysplastic group showed a statistically significant lowest mean percent while the severe dysplastic group showed a statistically significant highest mean percent followed by the moderately dysplastic group. This findings was in accordance with previous studies which suggest that CD133 may has a remarkable role in oral neoplastic transformation [7, 8] .
Similar to other previous researches, the expression of CD133 in our study was mainly cytoplasmic in all groups, but some dysplastic cells showed other patterns of expression such as membranous and nuclear expression which was in agreement with the expression pattern in gastric adenocarcinoma and hepatocarcinoma [14, 27, 28 ] .
It has been claimed that the cytoplasmic expression was undoubtedly linked to cancer development and metastasis occurrence and this cytoplasmic expression was considered as an independent prognostic factor. While the membranous expression has been observed in differentiated gastric carcinoma but no specific correlation was found between CD133 membranous expression and tumor progression [27, 29, 30] . So more investigations is needed to clarify the significance of the memraneous CD133 expression in oral cancer. Extensive CD133 nuclear expression have been associated with favorable prognosis in hepatocellular carcinoma cases other than cytoplasmic expression [29] . It is recognized that the function of some cellular proteins differs according to their site in the cells and CD133 may be one of these proteins [27] .
It is mentioned that CD133 overexpression stimulates the Wnt/b-catenin pathway, which in It has been reported also that CD133 prevents apoptosis and activates FLIP leading to cytotoxic drugs resistance [31] [32] [33] [34] .
The present study revealed stromal expression of CD133 in accordance to Margaritescu et al, 2001, results and these positively stained stromal cells could represent a mesenchymal adult stem cells that might participate in cancer development and progression through the stimulation of the tumor associated stroma [35] .
On the other hand, COX-2 is a one of molecular markers that correlates with malignant transformation, as several studies concluding it as early event in oral carcinogenesis [36] [37] [38] [39] [40] [41] .
In the present work, immunohistochemical study of COX-2 protein shown immunonegativity in all of the five cases of normal mucosa which is in consistence with the functional character of this isotype of COX family, where it is considered as an inducible protein mediating many of the inflammatory and carcinogenic processes in the tissues [42] . COX-2 immunonegativity in normal oral mucosa was a finding of many other investigators [36] [37] [38] [39] [40] 43] .
At the same time, all cases of oral epithelial dysplasias studied in this work showed positive COX-2 immunoreactivity. However, the extension and the intensity of the reaction were found to increase steadily as the grade of epithelial dysplasia amplified and this gradual increase was statistically significant which was in accordance with many previous studies that guaranteed the gradual increase in the intensity of COX-2 expression among the dysplasia gradient [36] [37] [38] [39] [40] .
The study of Gitta et al [44] could help the explanation of the basal immunolocalization of COX-2 that was observed in this study. They demonstrated a causative co-relation between the COX-2 overproduction in basal cells and the occurrence of both epithelial hyperplasia and dysplasia. They concluded that COX-2 overproduction appeared to allow epithelial cells proliferation by inhibiting their ingress in the post mitotic stage, which normally is combined with stimulating the expression of the differentiationrelated proteins. Upon overexpression of COX-2, the interaction of the cell with the surrounding cells and matrix components, which is essential for epithelial differentiation as well as keratinocyte polarity, thought to become disturbed.
Another research by Geun et al [45] correlated between COX-2 immunopositivity in the basal cell layer of squamous cell carcinoma and epithelial mesenchymal transition through an increase in Slug (a member of the Snail family that plays an important role in embryonic development) and a decrease in E-cadherin.
The gradual increase in COX-2 immuno expression amongst the layers of the dysplastic epithelium as the grade of the epithelial dysplasia increased, was a finding that was confirmed by the quantitative analysis of the area fraction of COX-2 immunopositive cells among the dysplasia gradient in this study.
The observation of the subcellular localization of COX-2 reaction among the different grades of oral epithelial dysplasia in the present work revealed a combination of cytoplasmic, perinuclear and nuclear reactions. The perinuclear accentuation of the COX-2 immunoexpression noticed in some cells in this study could be explained by the location of this protein in the nuclear envelope and inside the lumen of the endoplasmic reticulum, where the oxidizing climate support its appropriate dimerization [46] . The nuclear expression of COX-2 is harmonious with its role in mitogenesis. The existence of nuclear receptors, thats mediate some of the mitogenic effects of COX-2-derived PGs, confirms the functional link of COX-2 nuclear expression [47] .
On the other hand, the cytoplasmic localization of COX-2 observed in this work may be a direct consequence of proved identification of COX-2 protein inside the cytoplasmic lipid bodies, which seriously impacts tumor proliferation, by acting as an extra origin for the constant supply of PGs [48] . Also, the subcellular localization of COX-2 in the mitochondria of the tumor cells was relied to the protective role played by COX-2 against apoptosis that induced by oxidative stress [49] .
In accordance to previous studies [36-39, 41, 44,51] , our study revealed that the stromal cells showed a variable degree of COX-2 immunoreactivity together with the epithelial cells, thus, contributing to overall up-regulation of COX-2 expression in the lesion microenvironment. This was relied to the proved role of COX-2 in carcinogenesis via angiogenesis [45] [46] [47] [48] [49] and immunosuppression by IL-10 induction [52] .
The present study also showed a statistically significant direct positive correlation between the expression of CD133 and COX-2. This result is in accordance with Jeong Y. et al, 2018, study which clarified a significant strong interrelation between inflammation and the CSC in breast neoplasms. Similarly, Blaylock R., 2015, [53] mentioned that inflammation has a direct influence on stem cell DNA. Shigdar S. et al, 2014, [54] explained that cytokines of inflammatory response allow malignant cells to turn into CSCs through different signalling pathways.
Another explanation for the correlation between the expression of COX-2 and CD133 observed in this study could be related to the role of NF-κB pathway.
Activation of NF-κB promotes the production of mediators of the epithelial-mesenchymal transition (EMT) in malignant cells, so creating a CSC features [55] [56] [57] . At the same time, prostaglandin E(2) strongly shares with tumor necrosis factor-alpha to allow NF-kappaB-dependent gene activation [58, 59] . Also CSCs shows an increased level of inflammatory genes due to elevated NF-κB stimulation [60] . This inter-action between inflammation and stem cells could increase these two properties of tumor cells to further extend the CSC population [61] .
In addition, PGE2 has been related to the "phoenix rising pathway," in which tissue destruction starts a repair process. Many of chemotherapeutic drugs act by stimulation of apoptosis. It was reported that apoptotic cells could produce PGE2, that can activate the proliferation of CSCs, allowing more neoplastic cells growth and patient rebound [62] .
The growth of malignant stem cells in a spheroid colonies in the culture media indicates its continuous proliferation. The cells which express high COX-2 levels show more spherical pattern which emphasize the interaction between inflammation and stem cells characters [63, 64] .
Thus, the results of this study suggested that COX-2 not only share in malignant tumors development but also in controlling the stem cell proliferation in oral epithelial dysplasia and that there is a bidirectional interplay between inflammation and stemness in oral epithelia dysplasia. The presence of CSCs has a vital role in tumor resistance to cytotoxic drugs. Thus drugs that control the cyclooxygenase-2 expression might restrain stem cells growth and become a new anticancer strategy. [65] .
CONCLUSION
The gradual over expression of CD133 and COX-2 from normal to different grades of oral dysplastic lesions suggests the potential role of these both proteins in oral carcinogenesis. On the other hand, the positive correlation between CD133 and COX-2 in oral dysplastic lesions suggests that they might have functional link in oral malignant transformation and might help in the diagnosis and the prediction of the oral cancer development.
RECOMMENDATIONS
Future investigations is needed to study the correlation between inflammation and stem cell markers expression and actual development of oral squamous cell carcinoma. More investigations are needed to explore the relation between the role and the localization of CD133 in oral dysplastic cells.
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